Resource links provided by the National Library of Medicine
TSQM-9, Question 6 (convenience) – administration of THC:CBD as instructed: 84% of patients (n = 27) considered the administration of THC:CBD as instructed as being relatively easy to very easy. However, there was a substantial percentage in the cohort (16%; n = 5) regarding the administration of THC:CBD as inconvenient or very inconvenient.
THC:CBD is used in a wide dose range suggesting that the drug was applied on the basis of individual patients’ needs and preferences. Contributing to this notion, moderate to severe spasticity was associated with an elevated number of daily THC:CBD actuations and stronger recommendation rate (NPS) as compared to patients with mild spasticity. Overall, treatment satisfaction (TSQM-9) was high. The results suggest that THC:CBD may serve as a valuable addition in the spectrum of symptomatic therapy in ALS. However, prospective studies and head-to-head comparisons to other spasticity medications are of interest to further explore the effectiveness of THC:CBD in the management of spasticity, and other ALS-related symptoms.
n Number of patients; SD standard deviation
The study protocol was approved by the Medical Ethics Committee of the Charité – Universitätsmedizin Berlin, Germany under the number EA1/219/15. A signed patient information and informed consent form was obtained from all participating patients.
Total score for global satisfaction: ([sum (response score for question 7 plus question 8 plus question 9) minus 3] divided by 14) multiplied by 100.
TSQM-9, Question 2 (effectiveness) – the way THC:CBD relieves spasticity: 91% of patients (n = 29) were reasonably satisfied to very satisfied with the way how THC:CBD alleviated the symptoms of spasticity.
1 Centre for ALS and other motor neuron disorders, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
10 or 9 points: Likely recommendation:
The patient’s perception of spasticity and of spasticity-associated pain and cramps was recorded on the NRS, a one-dimensional assessment tool for recording the intensity of a symptom [16–19]. The 11-point scale ranges from 0 (no complaints) to 10 (worst imaginable complaints). The complaints are classified into four groups: